COMMENT

It ran into congestion last summer between $24-28, and is in the same range this year. $24 is key; if it falls below $24, it'll plunge to $20. If you want safety, look at the XRE-T instead.

HOLD
It bottomed last December at $10.21 and has now made a higher low, which is a good sign. If it rises above $13, it will see momentum, which has been lacking for quite a while. If it can rise above $13, it will signal momentum, which has been lacking lately. That breakout means it will reach $16 easily. Hold onto it.
DON'T BUY
It's in no-man's land now. Avoid new lows like this. This could fall to $5.
BUY
It made a low in December with a higher low in Februay. First resistance will be at $160, then at $182. If it breaks that, it will challenge its old $300 high. It participated in today's rally which is a good sign.
HOLD

He owns CP, which has a better profile. Don't sell CNR, but hold.

TOP PICK
He's very bullish gold. Good risk/reward for the next three months. He's recommended gold stocks elsewhere on this show, but this is a good basket of them.
TOP PICK
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
TOP PICK

Hit a high of $120 in Febuary 2018 and fell to $75 in December. It's now breaking resitance at $84. They just reported a 33% increase in EBITDA, and 40% increase in earnings. EPS is slightly down due to acquisitions. Estimates for this year are 24% and 48% higher next year. The Canadian Pension Board just invested in this. (Analysts’ price target is $90.73)